medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266562; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

# 1 Title

# 2 Childhood Immuno-metabolic Markers and Risk of Depression and Psychosis in

3 Adulthood: A Prospective Birth Cohort Study

# 4 Article Type

5 Original Research Paper

# 6 Authors

7 Donnelly NA<sup>1,2</sup>; Perry BI<sup>3,4</sup>; Jones HJ<sup>1,5,6</sup>; Khandaker, GM<sup>1,2,3,4,5.6</sup>

# 8 Affiliations

- 9 <sup>1</sup>Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School,
- 10 University of Bristol, Bristol, UK
- <sup>2</sup> Avon and Wiltshire Mental Health Partnership NHS Trust
- <sup>3</sup> Department of Psychiatry, University of Cambridge
- 13 <sup>4</sup> Cambridgeshire and Peterborough NHS Foundation Trust
- 14 <sup>5</sup>NIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, UK
- <sup>6</sup> MRC Integrative Epidemiology Unit, University of Bristol

# 16 Keywords

17 ALSPAC; Depression; Psychosis; Leptin; Adipokines; Negative Symptoms

# 18 Word Count

- 19 Total: 4091 words
- 20 Introduction: 613 words NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

21 Discussion: 1318 words

#### List of Figures and Tables 22

- The manuscript includes the following figures: 23
- 24 Figure 1: Correlations between Childhood Immuno-metabolic Markers
- Figure 2: Associations of Childhood Metabolic Hormones with Adult Depression and 25
- 26 **Psychosis Measures**
- 27 Figure 3: Associations of Childhood Immuno-Metabolic Factor Scores with Adult
- **Depression and Psychosis Measures** 28
- The manuscript includes the following tables: 29
- 30 Table 1: Associations of Childhood Metabolic Hormones with Adult Depression and
- Psychosis Measures in the Whole Sample 31
- Table 2: Associations of Childhood Immuno-Metabolic Factors with Adult Depression 32
- 33 and Psychosis Measures in the Whole Sample

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

# 34 Abstract

## 35 Background

- 36 Metabolic and inflammatory disorders commonly co-occur with depression and psychosis,
- 37 with emerging evidence implicating immuno-metabolic dysfunction in their aetiology.
- 38 Previous studies have reported metabolic dysfunction and inflammation in adults with
- 39 depression and psychosis. However, longitudinal studies testing the direction of association,
- 40 and the effects of different dimensions of early-life immuno-metabolic dysfunction on adult
- 41 psychopathology, are limited.

### 42 Methods

- 43 Using data from 3875 birth cohort participants we examined longitudinal associations of
- 44 three metabolic hormones (leptin, adiponectin, insulin) at age 9 with risks for depression-
- 45 and psychosis-spectrum outcomes at age 24. In addition, using nine immuno-metabolic
- 46 biomarkers, we constructed an exploratory bifactor model showing a general immuno-
- 47 metabolic factor and three specific factors (adiposity, inflammation, and insulin resistance),
- 48 which were also used as exposures.

## 49 Results

- 50 Childhood leptin was associated with adult depressive episode (adjusted odds ratio
- 51 (aOR)=1.28; 95% CI, 1.00-1.64) and negative symptoms (aOR=1.12; 95% CI, 1.05-1.20).
- 52 The general immuno-metabolic factor was associated with depressive symptoms
- 53 (aOR=1.05; 95% CI, 1.01-1.08) and psychotic experiences (aOR=1.20; 95% CI, 1.01-1.42).
- 54 The adiposity factor was associated with negative symptoms (aOR=1.07; 95% CI 1.02-1.12).
- All associations tended to be stronger in women, though 95% credible intervals overlapped
- 56 with that for men. In women, the inflammatory factor was associated with depressive
- episode (aOR=1.23; 95% CI, 1.01-1.47) and atypical depressive symptoms (aOR=1.10; 95%
- 58 CI, 1.02-1.19).

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

#### Conclusions 59

- While general immuno-metabolic dysfunction in childhood may contribute to risks for both 60
- psychotic and depressive symptoms in adulthood, childhood adiposity and inflammation are 61
- 62 linked to affective (depressive, atypical, and negative) symptoms.

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

#### 1. Introduction 63

64 Immuno-metabolic alterations are present in depressive and psychotic disorders, and are 65 associated with excess mortality (Hoang et al., 2013; Milaneschi et al., 2020, 2019; Vancampfort et al., 2015). The prevalence of cardiometabolic disease (Penninx et al., 2001; 66 67 van Melle et al., 2004), autoimmune inflammatory conditions (Benros et al., 2011; Eaton et al., 2006), and levels of circulating inflammatory markers (Khandaker et al., 2014; Osimo et 68 al., 2019), are higher in people with depression and psychosis compared with controls. 69 70 However, the direction of these relationships remains unclear. For example, while 71 psychotropic medications can increase predisposition to cardiometabolic disorders (Vancampfort et al., 2015), there is evidence that predisposition towards cardiometabolic 72 dysfunction predates treatment with psychotropic medications (Benseñor et al., 2012; Perry 73 et al., 2016, 2021b; Pillinger et al., 2017). Therefore, longitudinal studies are required to 74 75 address the issue of direction of association.

76 Emerging evidence from longitudinal studies suggests that inflammation may predate the 77 onset of depression and psychosis. Using longitudinal data from the Avon Longitudinal Study of Parents and Children (ALSPAC) and Northern Finland Birth Cohort (NFBC) 1986 birth 78 cohorts (Khandaker et al., 2014; Metcalf et al., 2017; Perry et al., 2021b), we have reported 79 80 associations between higher circulating levels of interleukin 6 (IL-6) and C-reactive protein (CRP) in childhood and adolescence with risk of depression and psychosis subsequently in 81 adulthood. Similar longitudinal associations have also been reported from the UK Whitehall 82 (Gimeno et al., 2009), Dutch Generation R (Zalli et al., 2016) and the Netherlands Study of 83 Depression and Anxiety (NESDA) (Lamers et al., 2020) cohorts. Using longitudinal repeated 84 measures data from the ALSPAC cohort, we have reported higher risk of psychosis in 85 adulthood associated with persistently high insulin levels across childhood, adolescence and 86 87 early-adulthood, which may vary by sex (Perry et al., 2021b). These findings point to a role of immuno-metabolic alterations in childhood, a critical period for the development of the 88 nervous, immune, and endocrine systems, in the aetiology of psychiatric disorders. 89

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

90 Despite previous studies reporting obesity, altered glucose-insulin homeostasis, lipids, and 91 other metabolic dysfunction in people with depression, psychosis and young people with psychotic experiences (Milaneschi et al., 2019; Perry et al., 2019; Vancampfort et al., 2015), 92 93 longitudinal studies of childhood metabolic markers and subsequent depression and 94 psychosis are relatively scarce. Particularly lacking are studies of metabolic hormones such 95 as insulin, adiponectin and leptin, which are key neuroendocrine regulators of energy 96 homeostasis. Immuno-metabolic biomarkers are interlinked and have pleiotropic functions. 97 For instance, obesity is associated with systemic low-grade inflammation (Timpson et al., 98 2011: Yudkin et al., 1999), while insulin and leptin are influenced by inflammation and 99 obesity (Considine et al., 1996; Jerry and Lesley, 2006; van Dielen et al., 2001). Commonly known as a satiety hormone, leptin is structurally similar to IL-6 and may have inflammatory 100 101 functions (Abella et al., 2017). Additionally, previous studies have typically considered only a 102 few immune or metabolic markers in isolation and ignored the underlying structure of covariance between biomarkers. 103

104 To address the issue of direction of association, we have carried out a longitudinal study 105 testing the associations of three key metabolic hormones (insulin, leptin and adjoonectin). 106 measured in childhood at age 9 years, with several outcomes across the spectrum of 107 depression (depressive episode, total symptom score, and atypical symptom score) and 108 psychosis (psychotic disorder, at-risk mental state, psychotic experiences, negative symptoms) at age 24 years, in a whole analysis sample and in men and women separately, 109 using data from the ALSPAC birth cohort. Furthermore, combining these hormones with 110 related immuno-metabolic markers (BMI, LDL, HDL, triglycerides, IL-6, and CRP), also 111 measured at age 9, we identified factors representing general and specific dimensions of 112 early-life immuno-metabolic dysfunction, and tested their associations with psychiatric 113 114 outcomes at age 24.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266562; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

# 115 2. Materials and Methods

# 116 2.1 Cohort Profile

117 We used data from the ALSPAC birth cohort (Boyd et al., 2013; Fraser et al., 2013;

118 Northstone et al., 2019), which recruited 14,541 pregnant women in the Avon area of the

119 United Kingdom between 1990 and 1992; of these initial pregnancies 13,988 children were

120 alive at 1 year of age. Further phases of recruitment occurred when the oldest children in the

121 cohort were approximately 7 years of age, resulting in an additional 913 children being

enrolled; giving a total cohort size of 15,454 pregnancies, resulting in 15,589 deliveries, of

123 which 14,901 were alive at 1 year of age. The study is considered to be representative of the

124 UK population (Golding et al., 2001).

125 Study data are collected and managed using the REDCap (Research Electronic Data

126 Capture) tools hosted at the University of Bristol (Harris et al., 2019, 2009). Children and

127 parents have been subsequently followed up with clinic and questionnaire assessments for a

128 range of health outcomes. The ALSPAC study website contains details of all available data

129 through a fully searchable data dictionary <u>http://www.bristol.ac.uk/alspac/researchers/our-</u>

130 <u>data/</u>.

131 Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee

132 and the Local Research Ethics Committees

133 (<u>http://www.bristol.ac.uk/alspac/researchers/research-ethics/).</u> Consent for biological

134 samples was collected in accordance with the UK Human Tissue Act (2004). Informed

135 consent for the use of data collected via questionnaires and clinics was obtained from

136 participants following the recommendations of the ALSPAC Ethics and Law Committee at

137 the time.

This study is reported in line with the Strengthening the Reporting of Observational Studiesin Epidemiology (STROBE) reporting guideline for cohort studies.

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

#### 2.2 Measurement of childhood immuno-metabolic biomarkers at age 9 141

142

#### 2.2.1 Metabolic Hormones 143

144 Leptin, adiponectin and random insulin were measured at the cohort age 9 clinic visit

(Supplementary Table 1). As previously described (Falaschetti et al., 2010), non-fasting 145

- 146 blood samples were collected during clinic visits, using standard aseptic procedure and
- immediately spun and frozen for long-term storage at -80°C. Blood biomarkers were 147
- assayed in 2008 after a median of 7.5 years in storage with no previous freeze-thaw cycles 148
- 149 during storage. We did not include fasting insulin in this study due to the lower sample size
- 150 available for that measure (Ong et al., 2004). Leptin (ng/ml) was measured by an in-house
- enzyme-linked immunosorbent assay (ELISA) validated against commercial methods. 151
- Adiponectin (ng/ml) and random insulin (mU/l) was measured using an ultrasensitive 152
- automated microparticle enzyme immunoassay (Mercodia), which does not cross-react with 153
- proinsulin. All assay coefficients of variation were <6%. 154
- 2.2.2 Other Metabolic Biomarkers 155
- 156 We included plasma lipids (LDL, HDL and triglycerides (mmol/l)), also measured at the
- cohort age 9 clinic visit (Supplementary Table 1). All were measured by a modification of 157
- the standard Lipid Research Clinics Protocol using enzymatic reagents for lipid 158
- determination. 159

#### 2.2.3 Inflammatory Biomarkers 160

- 161 We included IL-6 and CRP, which were also measured at the cohort age 9 clinic visit
- (Supplementary Table 1). IL-6 (pg/ml) was measured by ELISA (R&D systems, Abingdon, 162
- 163 UK), and CRP (mg/l) was measured by automated particle-enhanced immunoturbidimetric
- 164 assay (Roche UK, Welwyn Garden City, UK).

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

#### 2.3 Assessment of Psychiatric Outcomes at age 24 165

#### 2.3.1 Psychosis-Spectrum Outcomes 166

Psychotic positive symptoms were measured at age 24 with the psychosis-like symptoms 167 (PLIKS) interview (Sullivan et al., 2020; Zammit et al., 2013). Interviews were undertaken 168 using a semi-structured format by trained psychologists. Psychotic experiences (PEs) were 169 170 defined as symptoms in 3 domains (hallucinations, delusions, and thought interference) occurring in the 6 months prior to the interview. After cross-questioning, PEs were rated as 171 absent, suspected, or definite. We included definite PEs as our outcome of interest. 172 Psychotic disorder was defined as definite PLIKS, not attributable to sleep or fever, which 173 occurred at least once a month in the past 6 months, which either caused the respondent to 174

175 seek professional help, was very upsetting/distressing, and/or had a negative impact on their

social/occupational life. 176

Cases of At Risk Mental State (ARMS) were defined by mapping the Comprehensive 177

Assessment of the At Risk Mental State (CAARMS) criteria onto the PLIKS variables (Perry 178

179 et al., 2021b). ARMs were defined as participants meeting CAARMS criteria for attenuated

180 psychosis (symptoms not reaching the psychosis threshold owing to levels of intensity or

181 frequency), brief limited intermittent psychosis (frank psychotic symptoms that resolved

spontaneously within 1 week), or the CAARMS psychosis group. 182

183 Negative symptoms at age 24 were measured using ten guestions from a self-administered. 184 computerised version of the Community Assessment of Psychic Experiences (CAPE) questionnaire (Jones et al., 2016; Konings et al., 2006; Stefanis et al., 2002). We generated 185 186 a single outcome variable by dichotomising responses to each question (each item was rated by participants on a 1-4 scale, we grouped responses 1 and 2 as "symptom present". 187 188 scoring 1 and responses 3 and 4 as "symptom absent", scoring 0) and summing the 189 resultant scores, giving each participant a negative symptom score from 0 - 10.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266562; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

## 190 2.3.2 Depression Outcomes

Depressive symptoms at age 24 were measured using a self-administered, computerised 191 version of the Clinical Interview Schedule, Revised (CIS-R) (Lewis et al., 1992). We took 192 193 three outcomes from the CIS-R data: (1) a dichotomous depressive episode variable, based on a mapping of the CIS-R responses onto ICD-10 depression diagnostic criteria; (2) a 194 symptom score which was constructed as a sum of scores of the mood, thoughts, fatigue, 195 concentration, and sleep components for the CIS-R. This score ranged between 0 and 20. 196 197 We also derived (3): an atypical depression symptoms score composed of the sum of participants scores on 4 items from the CIS-R: increased appetite, increased weight, 198 199 hypersomnia and low energy. Note that the CIS-R does not contain a measure of "leaden 200 paralysis" as has been included in other measures of atypical depression (Lamers et al., 201 2020), as this measure is not part of many common depression screening instruments 202 (Fried, 2017).

### 203 2.3.3 Confounders

We included maternal social class (determined using occupational status) and maternal highest educational level as potential confounders. IL-6 and BMI at age 9 (weight in kg divided by height in meters squared) were also included for analyses where they were not part of the predictors.

208 2.4 Statistical Analysis

## 209 2.4.1 Data Transformation

210 We log<sub>10</sub>-transformed all metabolic measures to give approximately normally distributed

- 211 data, except for adiponectin, which was already approximately normally distributed. All
- continuous exposure and covariate variables were centred and standardised (mean value
- subtracted and then divided by the standard deviation). Therefore, odds ratios (ORs)
- represent change in outcome per SD change in exposure.

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

#### 2.4.2 Exploratory Factor Analysis 215

Using adiponectin, insulin, leptin, IL-6, CRP, HDL, LDL, triglycerides, and BMI, we explored 216 the underlying factor structure of the immuno-metabolic phenotype at age 9. Before analysis, 217 218 we inverted HDL to match the cardiometabolic risk-increasing direction of other markers. 219 Factor analysis was done using the exploratory factor analysis (EFA) function in the EFAtools R package. The number of factors was selected after inspecting the results of a 220 principal components analysis (Supplementary Methods, Supplementary Figure 2). We fit 221 a one factor, three factor, and a bifactor model with 3 subfactors, and compared model fit 222 223 (Supplementary Table 2). Compared to a one- or 3-factor model, the bifactor model was a better fit to our data. We then extracted factor scores for each factor for each subject (see 224 Supplementary Figure 2 and Supplementary Table 3 for factor loadings). 225

#### 226 2.4.3 Modelling Approach

We analysed data using R version 4.1.0 (R Development Core Team, 2017), fitting Bayesian 227 regression models using the brms (Bürkner, 2017) and rstanarm packages (Carpenter et al., 228 2017). As the number of participants providing data for different outcomes varied, we fit each 229 230 model to the largest possible dataset of complete cases for all covariates, exposures and

outcomes (see Supplementary Tables 4-6 for full details). 231

We fit unadjusted models with a psychiatric outcome predicted by our exposure variables of 232 233 interest (leptin, adiponectin and insulin). Next, we fit adjusted models with BMI at age 9, log<sub>10</sub> IL-6, sex at birth and maternal socioeconomic class included as covariates. We also fit 234 adjusted sex-stratified models to all female and male participants separately. For models 235 using factor scores as exposures, we included all factor scores as exposures plus sex at 236 237 birth and maternal socio-economic class as covariates.

238 We used regularising priors for all models (McElreath, 2018), calculating model estimate and the 95% credible interval, using the median and the highest density interval method. We 239 240 present as summary statistics the probability of direction, which can be considered

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266562; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpertuit.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- analogous to the frequentist p-value (Makowski et al., 2019a, 2019b), and the Region of
- 242 Practical Equivalence (ROPE), the proportion of the posterior falling within a set region
- around the null, here defined as an odds ratio in the range 0.9 1.1 (Kruschke and Liddell,
- 244 2018). See supplementary methods for further details.

## 245 2.4.4 Missing data

- 246 We analysed missingness in the dataset with two models: a model for missingness of clinic
- 247 data at age 9, with predictors of maternal education, maternal social class and ethnicity and
- sex of the child; and a model for missingness for age 24 psychiatric data in the set of
- 249 participants who had blood tests at age 9, with predictors of maternal education, maternal
- social class, ethnicity and sex of the child, and age 9 adiponectin, random insulin and leptin,
- 251 IL-6 and BMI.

## 252 2.4.5 Data Availability

- In line with the ALSPAC data access policy, all raw data used for the work presented can be
- accessed by other investigators by making a request to the ALSPAC study executive (see
- 255 http://www.bristol.ac.uk/alspac/researchers/access/).

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

#### 3. Results 256

#### 3.1 Childhood immuno-metabolic biomarker distributions, correlates, and 257

#### factor score calculation 258

Data on three metabolic hormones (insulin, leptin, adiponectin) and six related immuno-259

260 metabolic biomarkers (BMI, HDL, LDL, triglycerides, IL-6, and CRP) were available from

total 3,875 participants at age 9 (Supplementary Table 1). 261

- Higher leptin was associated with higher BMI (beta = 0.71; 95% credible interval [CI] 0.69-262
- 0.73), female sex (beta for girls compared to boys = 0.48; 95% Cl 0.44 0.51) and higher IL-263
- 6 (beta = 0.04; 95% CI 0.02-0.05). Higher adiponectin was associated with lower BMI (beta 264
- = -0.14; 95% CI -0.16 -0.11), female sex (beta = 0.12; 95% CI 0.07-0.18) and higher IL-6 265
- (beta = 0.04; 95% CI 0.01-0.06). Higher insulin was associated with higher BMI (beta = 0.22; 266

267 95% CI 0.19-0.25, see Supplementary Figure 1 and Supplementary Table 7).

Immuno-metabolic biomarkers were correlated (correlations ranged from -0.18 for 268

269 adiponectin-HDL to 0.75 for leptin-BMI, Figure 1). Using data for nine biomarkers we

calculated a bifactor model identifying a general immuno-metabolic factor (G, loading on all 270

271 biomarkers), and three sub-factors representing: (1) adiposity (loading on higher BMI, leptin

and LDL); (2) inflammation (loading on higher IL-6 and CRP); and (3) insulin resistance 272

273 (loading on higher triglycerides, insulin and lower HDL, **Supplementary Table 3**). There was


no relationship between sex or maternal class and G; all sub-factors had higher mean values 274

in females (Supplementary Table 8). 275

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266562; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis



276

277 Figure 1: Correlation between immuno-metabolic biomarkers at age 9 in the ALSPAC birth

278 *cohort*.

279 Matrix of correlations between all 9 immuno-metabolic markers measured at age 9. Colour

280 represents correlation; negative correlations are represented in blue, positive correlations in

red. Numerical values are correlation coefficients.


3.2 Associations of childhood metabolic hormones with depression and

- 283 psychosis risk in adulthood
- 284 3.2.1 Whole Sample Analysis
- After adjusting for potential confounders, leptin at age 9 was associated with depressive
- episode (adjusted odds ratio [aOR] =1.28; 95% CI, 1.00-1.64) and negative symptoms at
- age 24 (aOR=1.12; 95% CI 1.05-1.20). Adiponectin was also associated with negative
- symptoms (aOR=1.05; 95% CI 1.00-1.09 Figure 2, Table 1). Insulin was not associated with
- any psychiatric outcome in our total sample.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266562; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

### Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis



291

### 292 Figure 2: Associations of Childhood Metabolic Hormones with Adult Depression and

## 293 Psychosis Measures in the Whole Sample

Plots of estimated odds ratios for the effect of our exposures (adiponectin, insulin and leptin) on psychiatric outcomes at age 24. Data are presented unadjusted and adjusted (for sex in the all-participant model, IL-6 at age 9, BMI at age 9 and maternal social class) and grouped by model: all participants, only females or only males. Thin bars represent the 95% credible interval, thicker bars the 66% credible interval, and dots the median of the posterior distribution for that parameter.

# 300 Table 1: Associations of Childhood Metabolic Hormones with Adult Depression and Psychosis Measures in the Whole Sample

| Outcome                            | Exposure    | Unadjusted Analysis   |         |          | Adjusted Analysis     |       |          |
|------------------------------------|-------------|-----------------------|---------|----------|-----------------------|-------|----------|
|                                    |             | Estimated OR (95% CI) | pd      | ROPE (%) | Estimated OR (95% CI) | pd    | ROPE (%) |
| Depressive Episode                 | Leptin      | 1.24 (1.06, 1.46)     | 0.009   | 7.73     | 1.28 (1.00, 1.64)     | 0.055 | 12.64    |
|                                    | Adiponectin | 1.03 (0.88, 1.20)     | 0.692   | 74.39    | 1.00 (0.85, 1.17)     | 0.996 | 76.58    |
|                                    | Insulin     | 1.02 (0.88, 1.20)     | 0.796   | 76.26    | 1.05 (0.88, 1.23)     | 0.607 | 69.80    |
| Depressive Symptoms Score          | Leptin      | 1.08 (1.04, 1.11)     | < 0.001 | 93.48    | 1.03 (0.97, 1.08)     | 0.374 | 99.64    |
|                                    | Adiponectin | 0.99 (0.96, 1.02)     | 0.519   | 100.00   | 0.99 (0.95, 1.02)     | 0.437 | 100.00   |
|                                    | Insulin     | 1.01 (0.98, 1.04)     | 0.549   | 100.00   | 1.01 (0.98, 1.05)     | 0.456 | 100.00   |
| Atypical Depressive Symptoms Score | Leptin      | 1.11 (1.04, 1.18)     | 0.002   | 45.73    | 1.00 (0.90, 1.10)     | 0.987 | 95.25    |
|                                    | Adiponectin | 1.00 (0.94, 1.07)     | 0.937   | 99.88    | 1.00 (0.94, 1.06)     | 0.985 | 99.86    |
|                                    | Insulin     | 0.98 (0.93, 1.05)     | 0.611   | 99.70    | 0.98 (0.93, 1.04)     | 0.572 | 99.71    |
| Negative Symptoms Score            | Leptin      | 1.04 (0.99, 1.08)     | 0.103   | 99.83    | 1.12 (1.05, 1.20)     | 0.001 | 33.27    |
|                                    | Adiponectin | 1.05 (1.01, 1.10)     | 0.015   | 98.78    | 1.05 (1.00, 1.09)     | 0.038 | 99.25    |
|                                    | Insulin     | 1.02 (0.98, 1.06)     | 0.400   | 100.00   | 1.02 (0.98, 1.07)     | 0.296 | 99.94    |
| Psychotic Experiences              | Leptin      | 1.14 (0.96, 1.36)     | 0.161   | 35.93    | 0.96 (0.73, 1.27)     | 0.760 | 50.54    |
|                                    | Adiponectin | 0.97 (0.80, 1.16)     | 0.779   | 70.13    | 1.01 (0.84, 1.21)     | 0.924 | 71.41    |
|                                    | Insulin     | 1.16 (0.97, 1.39)     | 0.100   | 30.24    | 1.13 (0.95, 1.37)     | 0.182 | 39.36    |
| Psychotic Disorder                 | Leptin      | 1.11 (0.73, 1.60)     | 0.604   | 34.23    | 1.23 (0.75, 2.06)     | 0.433 | 22.66    |

# Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

|                | Adiponectin | 1.05 (0.71, 1.53) | 0.817 | 38.34 | 1.01 (0.66, 1.48) | 0.957 | 37.18 |
|----------------|-------------|-------------------|-------|-------|-------------------|-------|-------|
|                | Insulin     | 1.09 (0.73, 1.59) | 0.674 | 35.45 | 1.11 (0.74, 1.62) | 0.589 | 33.36 |
| Psychosis ARMS | Leptin      | 0.95 (0.61, 1.40) | 0.793 | 36.58 | 1.21 (0.72, 2.00) | 0.449 | 22.96 |
|                | Adiponectin | 0.98 (0.65, 1.45) | 0.938 | 37.08 | 0.94 (0.63, 1.39) | 0.780 | 36.27 |
|                | Insulin     | 0.87 (0.59, 1.26) | 0.494 | 31.34 | 0.91 (0.62, 1.31) | 0.629 | 34.92 |

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

#### 302 3.2.2 Sex-Stratified Analysis

- The associations of leptin with depressive episode (aOR=1.42; 95% CI 1.04-1.91), depressive 303
- symptoms (aOR=1.09; 95% CI 1.01-1.18) and negative symptoms (aOR=1.18; 95% CI 1.07-1.29) 304
- 305 were stronger in women, as was the associations of adiponectin (aOR=1.07; 95% CI 1.01-1.13)
- and of insulin (aOR =1.08; 95% CI 1.01-1.14) with negative symptoms, although credible intervals 306
- 307 overlapped with those for men (Supplementary Tables 9&10).
- 3.3 Associations of childhood immuno-metabolic factor scores with depression and 308
- psychosis risk in adulthood 309
- 3.3.1 Whole Sample Analysis 310
- 311 The general immuno-metabolic factor, G, was associated with depression symptom score
- (OR=1.05; 95% CI 1.01-1.08) and psychotic experiences at age 24 (aOR=1.20; 95% CI 1.01-1.42, 312
- 313 Figure 3, Table 2). The adiposity factor was associated with negative symptoms (aOR=1.07; 95%
- CI 1.02-1.12). 314

#### 3.3.2 Sex-Stratified Analysis 315

- There was stronger evidence of association between G and psychopathology in women than men. 316
- In women, G was associated with depression symptom score (aOR=1.05; 95% CI 1.01-1.09), 317


318 atypical depression (aOR=1.07; 95% CI 1.00-1.15), and psychotic experiences (aOR=1.25; 95% CI

1.01-1.52, **Supplementary Tables 11&12**) although credible intervals overlapped with those for 319 320 men.

The inflammatory factor was associated with depressive episodes (aOR=1.23: 95% CI 1.01-1.47) 321 and atypical depressive symptoms in women (aOR=1.10; 95% CI 1.02-1.19). The adiposity factor 322 323 was associated with negative symptoms in women (aOR=1.09; 95% CI 1.03-1.16). The insulin resistance factor was not associated with any psychiatric outcomes at age 24. However, point 324 estimates for the association between the insulin resistance factor and psychosis-related outcomes 325 (PEs, ARMS, psychotic disorder) were considerably larger in men compared with women, although 326 credible intervals were relatively wide (Figure 3). 327

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266562; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.





328

329 Figure 3: Associations of Childhood Immuno-Metabolic Factors with Adult Depression and

## 330 Psychosis Measures in the Whole Sample

Plots of estimated odds ratios for the effect of factor scores derived from a bifactor EFA model (general factor (*G*) and three subfactors:(1) adiposity (*ADI*), (2) inflammation (*INF*) and (3) insulin resistance (*IR*) on psychiatric outcomes at age 24. Data are adjusted (for maternal social class and sex in the all-participant model) and grouped by model: either all participants, only females or only males. Thin bars represent the 95% credible interval, thicker bars the 66% credible interval, and dots the median of the posterior distribution for that parameter.

### It is made available under a CC-BY-ND 4.0 International license Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

## 338 Table 2: Associations of Childhood Immuno-Metabolic Factors with Adult Depression and

## 339 Psychosis Measures in the Whole Sample

| Outcome               | Exposure                   | Estimated OR      | pd    | ROPE   |  |
|-----------------------|----------------------------|-------------------|-------|--------|--|
|                       | (Immuno-metabolic Factors) | (95% CI)          |       | (%)    |  |
| Depressive Episode    | General factor             | 1.02 (0.87, 1.18) | 0.843 | 79.33  |  |
|                       | Adiposity factor           | 1.14 (0.97, 1.35) | 0.121 | 34.71  |  |
|                       | Inflammation factor        | 1.13 (0.97, 1.33) | 0.141 | 40.11  |  |
|                       | Insulin resistance factor  | 1.04 (0.88, 1.22) | 0.670 | 73.37  |  |
| Depressive Symptoms   | General factor             | 1.05 (1.01, 1.08) | 0.008 | 99.97  |  |
| Score                 | Adiposity factor           | 1.03 (0.99, 1.07) | 0.107 | 99.98  |  |
|                       | Inflammation factor        | 0.99 (0.96, 1.03) | 0.626 | 100.00 |  |
|                       | Insulin resistance factor  | 0.98 (0.95, 1.02) | 0.328 | 100.00 |  |
| Atypical Depressive   | General factor             | 1.06 (1.00, 1.12) | 0.063 | 93.41  |  |
| Symptom Score         | Adiposity factor           | 1.03 (0.97, 1.10) | 0.339 | 98.12  |  |
|                       | Inflammation factor        | 1.06 (1.00, 1.13) | 0.069 | 91.38  |  |
|                       | Insulin resistance factor  | 0.99 (0.93, 1.05) | 0.796 | 99.83  |  |
| Negative Symptoms     | General factor             | 0.97 (0.93, 1.01) | 0.130 | 99.92  |  |
| Score                 | Adiposity factor           | 1.07 (1.02, 1.12) | 0.005 | 92.45  |  |
|                       | Inflammation factor        | 1.03 (0.99, 1.07) | 0.191 | 99.98  |  |
|                       | Insulin resistance factor  | 1.00 (0.95, 1.04) | 0.861 | 100.00 |  |
| Psychotic Experiences | General factor             | 1.20 (1.01, 1.42) | 0.029 | 15.84  |  |
|                       | Adiposity factor           | 1.12 (0.93, 1.36) | 0.226 | 41.93  |  |
|                       | Inflammation factor        | 1.02 (0.85, 1.22) | 0.850 | 69.88  |  |
|                       | Insulin resistance factor  | 0.97 (0.81, 1.16) | 0.754 | 70.36  |  |
| Psychotic Disorder    | General factor             | 0.90 (0.62, 1.32) | 0.570 | 34.57  |  |
|                       | Adiposity factor           | 1.09 (0.72, 1.59) | 0.673 | 34.12  |  |
|                       | Inflammation factor        | 1.27 (0.86, 1.82) | 0.234 | 19.64  |  |

It is made available under a CC-BY-ND 4.0 International license Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

|                | Insulin resistance factor | 1.10 (0.75, 1.65) | 0.621 | 33.89 |
|----------------|---------------------------|-------------------|-------|-------|
| Psychosis ARMS | General factor            | 0.76 (0.50, 1.13) | 0.171 | 16.25 |
|                | Adiposity factor          | 0.98 (0.63, 1.47) | 0.942 | 35.86 |
|                | Inflammation factor       | 0.96 (0.64, 1.44) | 0.854 | 36.54 |
|                | Insulin resistance factor | 1.17 (0.79, 1.73) | 0.427 | 28.33 |

340

## 341 3.4 Missing Data

Out of total 15,645 participants enrolled in ALSPAC at inception, 3,875 contributed clinic and

343 covariate data up to age 9, and up to 3,966 participants contributed psychiatric data at age 24

344 (**Supplementary Table 13**). A maximum of 1,611 participants contributed both exposure and

outcome data (~10% of the total cohort, ~40% of all participants with outcome data). Therefore,

- 346 there was substantial missingness in our dataset.
- In a sample of participants who contributed all demographic, age 9 immuno-metabolic exposures
- and covariate data (n = 3,863), male sex (aOR=2.32; 95% CI 2.02-2.68), lower maternal education
- 349 (aOR=0.39; 95% CI 0.29-0.50), lower maternal social class (aOR=0.62; 95% CI 0.40-0.95), and
- higher adiponectin levels at age 9 (aOR=1.08; 95% CI 1.01-1.16) were associated with missing
- 351 psychiatric outcome data at age 24 (**Supplementary Table 14)**.

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

# 4. Discussion

## 353 4.1 Main Findings

Using data from a prospective birth cohort, we report that childhood leptin and adiponectin are 354 355 associated with largely affective symptoms (depression and psychosis negative symptoms) in adulthood. Evidence for these associations remained after controlling for covariates including BMI 356 357 and inflammation and was stronger in women. Exploratory Factor Analysis of metabolic and 358 inflammatory biomarkers revealed an underlying structure of covariance, where a general immuno-359 metabolic factor was associated with both depressive symptoms and psychotic experiences. We also identified three specific factors. Leptin and BMI loaded onto the adiposity factor, which was 360 associated with negative symptoms. The inflammatory factor was associated with depressive 361 episode and atypical depressive symptoms in women. We found no associations between the 362 363 insulin resistance factor and psychiatric outcomes, although the point estimates for psychosisrelated outcomes were considerably larger in men than women. 364

## 365 4.2 Comparison with Previous Studies

The association between leptin and negative symptoms is in keeping with a meta-analysis of 366 patients with schizophrenia (Stubbs et al., 2016), although this was not observed in smaller studies 367 368 of first episode of psychosis (FEP) patients (Chouinard et al., 2019; Lis et al., 2020). However, in FEP cases Lis et al., (2020) observed a correlation between leptin and cognitive dysfunction, a 369 domain of psychopathology somewhat linked to negative symptoms. Recently, a Mendelian 370 randomisation (MR) study did not find an association between leptin and schizophrenia (Perry et 371 al., 2021a), bringing into question whether leptin plays a causal role in the illness. It is worth noting 372 373 that this MR analysis relied on GWAS of schizophrenia, and not that of negative symptoms specifically. Therefore, replication of our findings in other longitudinal cohorts, as well as evidence 374 triangulation using complementary methods like MR based on GWAS of negative symptoms are 375 required to fully understand the relationship between leptin and negative symptoms. 376

Lack of association between childhood random insulin levels, or the insulin resistance factor, and
 positive psychotic symptoms at age 24 is consistent with a previous study from the ALSPAC cohort

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266562; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

379 testing association between fasting insulin and psychosis-spectrum outcomes at age 18 (Perry et al., 2019). However, using longitudinal repeat measure data, Perry et al., (2021b) recently reported 380 that persistently raised fasting insulin levels through childhood and adolescence is associated with 381 psychosis risk at age 24. Together, these findings suggest that persistently high leptin during 382 383 development is likely relevant for adult psychosis, rather than one-off measures which do not 384 consider variation in leptin levels over time. Nevertheless, similar to Perry et al., (2021b), we observed stronger association between the insulin resistance factor and psychosis-related 385 386 outcomes in men compared with women, suggesting that early-life insulin resistance may contribute to psychosis risk in men particularly. 387

## 4.3 Potential mechanism of associations of immuno-metabolic markers and

## 389 depressive and psychotic symptoms

We observed that adiposity and inflammation were largely associated with negative and atypical 390 depressive symptoms. There is a rich literature suggesting a role of low-grade systemic 391 inflammation in depression (Khandaker et al., 2017; Milaneschi et al., 2021, 2020). Our findings 392 393 are consistent with a previous genetic study showing that cases of atypical depression (defined by increased appetite and/or weight) have higher genetic predisposition for obesity and inflammation. 394 395 particularly genetic risk variants for BMI, leptin, and CRP (Milaneschi et al., 2017). Similarly, recent 396 MR studies from the UK Biobank and Dutch NESDA cohorts have reported associations of higher 397 BMI and IL-6 with specific depressive symptoms such as fatigue and appetite change (Kappelmann et al., 2021; Milaneschi et al., 2021). The mechanism of the association between 398 inflammation and depression, particularly atypical depressive symptoms (Lamers et al., 2020), has 399 400 been hypothesised to involve the activation of sickness-related behaviours by inflammatory 401 cytokines, which directly affect neuroendocrine systems involved in regulating mood and 402 homeostatic functions such as sleep and appetite (Milaneschi et al., 2020). Further work is needed to understand how leptin, and adiposity in general, contribute to negative symptoms. 403 Negative symptoms are common in schizophrenia, with prevalence exceeding 50% (Bobes et al., 404

405 2010), and are a major contributor to morbidity (Fervaha et al., 2014; lasevoli et al., 2018).

Furthermore, there is only a limited evidence base for effective treatments for these symptoms
 23

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266562; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license . Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

407 (Galderisi et al., 2021). Previous work suggests two latent factors underlying negative symptoms,

namely reduced expression and amotivation (Bucci and Galderisi, 2017). Studies in schizophrenia 408 409 suggest an association between amotivational negative symptoms and altered reward processing, which involves brain regions associated with the dopamine system including the ventral striatum 410 411 and medial prefrontal cortex (Strauss et al., 2016; Vanes et al., 2018; Wang et al., 2015; Wolf et 412 al., 2014). Leptin has been demonstrated to both indirectly and directly affect the activity of midbrain dopamine neurons in animal models (Hommel et al., 2006; Leinninger et al., 2009), as 413 has adiponectin (Sun et al., 2019). Furthermore, a relationship between inflammation, brain reward 414 415 systems and negative symptoms has been proposed (Goldsmith and Rapaport, 2020), which leptin could also modulate, given evidence of its interactions with immune system (Abella et al., 2017; 416 Pulito-Cueto et al., 2020). Therefore, adipokines could have a direct influence on immune and 417

418 neural networks involved in the pathogenesis of negative symptoms.

### 419 4.4 Strengths and Limitations

We used prospective data with exposures measured approximately 15 years prior to that of outcomes. We used a Bayesian approach to our statistical analysis, which is relatively novel and allowed the incorporation of prior information, and the generation of point estimates and credible intervals which have a more intuitive and robust interpretation than frequentist confidence intervals and p-values (Wagenmakers et al., 2018).

Limitations include missing data and pattern of missingness. Participants were not missing completely at random. Analysis of missingness in exposure data revealed that social class, and education influenced participation in the study. The complete case data came from a group from higher social class and higher educated families. One of the exposures, adiponectin, was associated with missingness, which might have introduced bias. Furthermore, >97% of the ALSPAC cohort is of white ethnicity, and so representativeness is an issue, and further studies in more diverse populations are required.

We used an exploratory factor analysis approach to derive immuno-metabolic factors. In future,confirmation of these findings in an independent dataset using confirmatory factor analysis is

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266562; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

required. Bifactor models have a tendency to overfitting (Bonifay and Cai, 2017) and we were

435 limited to nine immuno-metabolic biomarkers available from the age 9 ALSPAC cohort clinic

436 assessment. In future, inclusion of a wider range of biomarkers may help to improve latent factor

437 estimation. Nevertheless, without pre-specifying the biomarkers that might contribute to each latent

438 factor, we identified three specific factors (adiposity, inflammation, and insulin resistance)

439 composed of individual biomarkers with established, intuitive links with each factor, giving our

440 findings face validity.

441 Methods for calculating factor scores are imprecise, and scores are inherently indeterminate

442 (Grice, 2001). Therefore, the use of extracted factor scores as exposures in separate models may

have introduced error. However, the approach of combining factor scores with other datasets for

444 further analysis, including by Bayesian approaches, has been previously applied (Dam et al., 2017;

Gagne et al., 2020), and can contribute exploratory information to inform future studies. A future

446 approach that combines (potentially longitudinally measured) biomarkers with latent factors and

447 psychiatric outcomes in a single (Bayesian) structural equation model might inform a deeper

448 understanding of the relationship between individual biomarkers, useful intermediate concepts

449 (latent factors), and individual symptoms or psychopathological constructs.

## 450 4.5 Conclusions

Using a prospective cohort study, we report that childhood levels of the metabolic hormones leptin 451 452 and adiponectin are associated with depressive and negative symptoms in early adulthood. These associations are stronger in women than men. Somewhat distinct associations were seen for 453 immuno-metabolic factor scores, which were derived from nine immuno-metabolic measures. 454 While a general immuno-metabolic factor was associated with both depressive and psychotic 455 symptoms, inflammation and adiposity were particularly associated with affective (depressive, 456 atypical depressive, and negative) symptoms. Together, these findings are consistent with the idea 457 that childhood immuno-metabolic alterations may contribute to risk of depressive and psychotic 458 459 disorders in adulthood.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266562; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

# 460 Acknowledgements

- The authors would like to thank Nils Kappelmann for valuable discussions about statistical analysis and atypical depression. We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
- 467

# 468 Funding Sources

469 The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of

470 Bristol provide core support for ALSPAC. A comprehensive list of grant funding is available on the

471 ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf).

The outcome data from age 24 was specifically funded by MRC grants MR/L022206/1 and

473 MR/M006727/1.

474 NAD acknowledges funding support from a National Institute for Health Research Academic Clinical 475 Fellowship in Mental Health. BIP acknowledges funding support from the National Institute for Health 476 Research (NIHR) (Doctoral Research Fellowship Grant No. DRF-2018-11-ST2-018). HJJ 477 acknowledges support from the NIHR Bristol Biomedical Research Centre. GMK acknowledges 478 funding support from the Wellcome Trust (Grant No. 201486/Z/16/Z), the Medical Research Council 479 (Grant No. MC\_PC\_17213, Grant No. MR/S037675/1, and Grant No. MR/W014416/1), The MQ: 480 Transforming Mental Health (Grant No. MQDS17/40), and the BMA Foundation (J. Moulton Grant 481 2019).

# 482 Competing Interests

483 The authors declare they have no competing interests

484

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

#### **CRediT** author statement 485

- Nicholas Donnelly: Conceptualisation; Software; Data Curation; Formal Analysis; Visualization; Writing 486
- 487 - Original Draft
- 488 Benjamin Perry: Data Curation; Writing - Review & Editing
- 489 Hannah Jones: Writing - Reviewing & Editing
- Golam Khandaker: Conceptualization; Supervision; Writing Reviewing & Editing; Funding acquisition 490

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266562; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percentity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

## 491 References

- 492 Abella, V., Scotece, M., Conde, J., Pino, J., Gonzalez-Gay, M.A., Gómez-Reino, J.J., Mera, A., Lago,
- 493 F., Gómez, R., Gualillo, O., 2017. Leptin in the interplay of inflammation, metabolism and
- 494 immune system disorders. Nat. Rev. Rheumatol. 13, 100–109.
- 495 https://doi.org/10.1038/nrrheum.2016.209
- Benros, M.E., Nielsen, P.R., Nordentoft, M., Eaton, W.W., Dalton, S.O., Mortensen, P.B., 2011.
- 497 Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year
- 498 population-based register study. Am. J. Psychiatry 168, 1303–1310.
- 499 https://doi.org/10.1176/appi.ajp.2011.11030516
- Benseñor, I.M., Brunoni, A.R., Pilan, L.A., Goulart, A.C., Busatto, G.F., Lotufo, P.A., Scazufca, M.,
- 501 Menezes, P.R., 2012. Cardiovascular risk factors in patients with first-episode psychosis in São
- 502 Paulo, Brazil. Gen. Hosp. Psychiatry 34, 268–275.
- 503 https://doi.org/10.1016/j.genhosppsych.2011.12.010
- Bobes, J., Arango, C., Garcia-Garcia, M., Rejas, J., CLAMORS Study Collaborative Group, 2010.
- 505 Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated
- 506 with antipsychotics in routine clinical practice: findings from the CLAMORS study. J. Clin.
- 507 Psychiatry 71, 280–286. https://doi.org/10.4088/JCP.08m04250yel
- Bonifay, W., Cai, L., 2017. On the Complexity of Item Response Theory Models. Multivar. Behav. Res.
   52, 465–484. https://doi.org/10.1080/00273171.2017.1309262
- 510 Boyd, A., Golding, J., Macleod, J., Lawlor, D.A., Fraser, A., Henderson, J., Molloy, L., Ness, A., Ring,
- 511 S., Davey Smith, G., 2013. Cohort Profile: The 'Children of the 90s'—the index offspring of the
- 512 Avon Longitudinal Study of Parents and Children. Int. J. Epidemiol. 42, 111–127.
- 513 https://doi.org/10.1093/ije/dys064
- Bucci, P., Galderisi, S., 2017. Categorizing and assessing negative symptoms. Curr. Opin. Psychiatry
   30, 201–208. https://doi.org/10.1097/YCO.00000000000322
- 516 Bürkner, P.-C., 2017. brms: An R Package for Bayesian Multilevel Models Using Stan. J. Stat. Softw.
- 517 80, 1–28. https://doi.org/10.18637/jss.v080.i01

It is made available under a CC-BY-ND 4.0 International license Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

518 Carpenter, B., Gelman, A., Hoffman, M.D., Lee, D., Goodrich, B., Betancourt, M., Brubaker, M., Guo,

- J., Li, P., Riddell, A., 2017. Stan: A Probabilistic Programming Language. J. Stat. Softw. 76, 1–
- 520 32. https://doi.org/10.18637/jss.v076.i01
- 521 Chouinard, V.-A., Henderson, D.C., Man, C.D., Valeri, L., Gray, B.E., Ryan, K.P., Cypess, A.M.,
- 522 Cobelli, C., Cohen, B.M., Öngür, D., 2019. Impaired insulin signaling in unaffected siblings and
- 523 patients with first episode psychosis. Mol. Psychiatry 24, 1513–1522.
- 524 https://doi.org/10.1038/s41380-018-0045-1
- 525 Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce, M.R.,
- 526 Ohannesian, J.P., Marco, C.C., McKee, L.J., Bauer, T.L., Caro, J.F., 1996. Serum
- 527 Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans. N. Engl. J. Med.
- 528 334, 292–295. https://doi.org/10.1056/NEJM199602013340503
- 529 Dam, N.T.V., O'Connor, D., Marcelle, E.T., Ho, E.J., Craddock, R.C., Tobe, R.H., Gabbay, V.,
- 530 Hudziak, J.J., Castellanos, F.X., Leventhal, B.L., Milham, M.P., 2017. Data-Driven Phenotypic
- 531 Categorization for Neurobiological Analyses: Beyond DSM-5 Labels. Biol. Psychiatry 81, 484–
- 532 494. https://doi.org/10.1016/j.biopsych.2016.06.027
- Eaton, W.W., Byrne, M., Ewald, H., Mors, O., Chen, C.-Y., Agerbo, E., Mortensen, P.B., 2006.
- 534 Association of schizophrenia and autoimmune diseases: linkage of Danish national registers.
- 535 Am. J. Psychiatry 163, 521–528. https://doi.org/10.1176/appi.ajp.163.3.521
- 536 Falaschetti, E., Hingorani, A.D., Jones, A., Charakida, M., Finer, N., Whincup, P., Lawlor, D.A., Davey
- 537 Smith, G., Sattar, N., Deanfield, J.E., 2010. Adiposity and cardiovascular risk factors in a large
- 538 contemporary population of pre-pubertal children. Eur. Heart J. 31, 3063–3072.
- 539 https://doi.org/10.1093/eurheartj/ehq355
- 540 Fervaha, G., Foussias, G., Agid, O., Remington, G., 2014. Motivational and neurocognitive deficits are 541 central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatr.
- 542 Scand. 130, 290–299. https://doi.org/10.1111/acps.12289
- 543 Fraser, A., Macdonald-Wallis, C., Tilling, K., Boyd, A., Golding, J., Davey Smith, G., Henderson, J.,
- 544 Macleod, J., Molloy, L., Ness, A., Ring, S., Nelson, S.M., Lawlor, D.A., 2013. Cohort Profile:
- 545 The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int. J.
- 546 Epidemiol. 42, 97–110. https://doi.org/10.1093/ije/dys066

It is made available under a CC-BY-ND 4.0 International licen Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

547 Fried, E.I., 2017. The 52 symptoms of major depression: Lack of content overlap among seven

- 548 common depression scales. J. Affect. Disord. 208, 191–197.
- 549 https://doi.org/10.1016/j.jad.2016.10.019
- 550 Gagne, C., Zika, O., Dayan, P., Bishop, S.J., 2020. Impaired adaptation of learning to contingency
- volatility in internalizing psychopathology. eLife 9, e61387. https://doi.org/10.7554/eLife.61387
- 552 Galderisi, S., Kaiser, S., Bitter, I., Nordentoft, M., Mucci, A., Sabé, M., Giordano, G.M., Nielsen, M.Ø.,
- 553 Glenthøj, L.B., Pezzella, P., Falkai, P., Dollfus, S., Gaebel, W., 2021. EPA guidance on
- 554 treatment of negative symptoms in schizophrenia. Eur. Psychiatry 64, e21.
- 555 https://doi.org/10.1192/j.eurpsy.2021.13
- 556 Gimeno, D., Kivimäki, M., Brunner, E.J., Elovainio, M., De Vogli, R., Steptoe, A., Kumari, M., Lowe,
- 557 G.D.O., Rumley, A., Marmot, M.G., Ferrie, J.E., 2009. Associations of C-reactive protein and
- 558 interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study.
- 559 Psychol. Med. 39, 413–423. https://doi.org/10.1017/S0033291708003723
- Golding, Pembrey, Jones, Team, T.A.S., 2001. ALSPAC–The Avon Longitudinal Study of Parents and
   Children. Paediatr. Perinat. Epidemiol. 15, 74–87. https://doi.org/10.1046/j.1365-
- 562 3016.2001.00325.x
- Goldsmith, D.R., Rapaport, M.H., 2020. Inflammation and Negative Symptoms of Schizophrenia:
   Implications for Reward Processing and Motivational Deficits. Front. Psychiatry 11, 46.
- 565 https://doi.org/10.3389/fpsyt.2020.00046
- Grice, J., 2001. Computing and evaluating factor scores. Psychol. Methods 6, 430–50.
- Harris, P.A., Taylor, R., Minor, B.L., Elliott, V., Fernandez, M., O'Neal, L., McLeod, L., Delacqua, G.,
  Delacqua, F., Kirby, J., Duda, S.N., REDCap Consortium, 2019. The REDCap consortium:
  Building an international community of software platform partners. J. Biomed. Inform. 95,
  103208. https://doi.org/10.1016/j.jbi.2019.103208
- Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., Conde, J.G., 2009. Research electronic
- 572 data capture (REDCap)--a metadata-driven methodology and workflow process for providing
- 573 translational research informatics support. J. Biomed. Inform. 42, 377–381.
- 574 https://doi.org/10.1016/j.jbi.2008.08.010

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis Hoang, U., Goldacre, M.J., Stewart, R., 2013. Avoidable mortality in people with schizophrenia or 575

- bipolar disorder in England. Acta Psychiatr. Scand. 127, 195–201. 576
- 577 https://doi.org/10.1111/acps.12045
- Hommel, J.D., Trinko, R., Sears, R.M., Georgescu, D., Liu, Z.W., Gao, X.B., Thurmon, J.J., Marinelli, 578
- M., DiLeone, R.J., 2006. Leptin receptor signaling in midbrain dopamine neurons regulates 579 feeding. Neuron 51, 801-810. 580
- 581 Iasevoli, F., Avagliano, C., Altavilla, B., Barone, A., D'Ambrosio, L., Matrone, M., Notar Francesco, D.,
- Razzino, E., de Bartolomeis, A., 2018. Disease Severity in Treatment Resistant Schizophrenia 582
- Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive 583
- Dysfunctions and Neurological Soft Signs. Front. Psychiatry 9, 553. 584
- https://doi.org/10.3389/fpsyt.2018.00553 585
- Jerry, R.G., Lesley, V.C., 2006. Relationship Between Inflammation, Insulin Resistance and Type 2 586 Diabetes: Cause or Effect? Curr. Diabetes Rev. 2, 195-211. 587
- Jones, H.J., Stergiakouli, E., Tansey, K.E., Hubbard, L., Heron, J., Cannon, M., Holmans, P., Lewis, 588
- 589 G., Linden, D.E.J., Jones, P.B., Davey Smith, G., O'Donovan, M.C., Owen, M.J., Walters, J.T.,
- 590 Zammit, S., 2016. Phenotypic Manifestation of Genetic Risk for Schizophrenia During
- 591 Adolescence in the General Population. JAMA Psychiatry 73, 221.
- 592 https://doi.org/10.1001/jamapsychiatry.2015.3058
- 593 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M.,
- 594 Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation,
- and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian 595
- Randomization Study, JAMA Psychiatry 78, 161–170. 596
- 597 https://doi.org/10.1001/jamapsychiatry.2020.3436
- 598 Khandaker, G.M., Dantzer, R., Jones, P.B., 2017. Immunopsychiatry: important facts. Psychol. Med. 47, 2229-2237. https://doi.org/10.1017/S0033291717000745 599
- Khandaker, G.M., Pearson, R.M., Zammit, S., Lewis, G., Jones, P.B., 2014. Association of serum 600
- interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult 601
- life: a population-based longitudinal study. JAMA Psychiatry 71, 1121–1128. 602
- https://doi.org/10.1001/jamapsychiatry.2014.1332 603

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis 604 Konings, M., Bak, M., Hanssen, M., van Os, J., Krabbendam, L., 2006. Validity and reliability of the

- CAPE: a self-report instrument for the measurement of psychotic experiences in the general 605
- 606 population. Acta Psychiatr. Scand. 114, 55-61. https://doi.org/10.1111/j.1600-
- 607 0447.2005.00741.x
- Kruschke, J.K., Liddell, T.M., 2018. Bayesian data analysis for newcomers. Psychon. Bull. Rev. 25, 608 609 155-177. https://doi.org/10.3758/s13423-017-1272-1
- 610 Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H., 2020.
- Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the 611
- NESDA study. Brain. Behav. Immun. 88, 174–183. https://doi.org/10.1016/j.bbi.2020.04.002 612
- Leinninger, G.M., Jo, Y.-H., Leshan, R.L., Louis, G.W., Yang, H., Barrera, J.G., Wilson, H., Opland, 613
- D.M., Faouzi, M.A., Gong, Y., 2009. Leptin Acts via Leptin Receptor-Expressing Lateral 614
- Hypothalamic Neurons to Modulate the Mesolimbic Dopamine System and Suppress Feeding. 615
- Cell Metab. 10, 89-98. https://doi.org/10.1016/j.cmet.2009.06.011 616
- Lewis, G., Pelosi, A.J., Araya, R., Dunn, G., 1992. Measuring psychiatric disorder in the community: a 617 618 standardized assessment for use by lay interviewers. Psychol. Med. 22, 465-486.
- 619 https://doi.org/10.1017/s0033291700030415
- Lis, M., Stańczykiewicz, B., Pawlik-Sobecka, L., Samochowiec, A., Reginia, A., Misiak, B., 2020. 620
- 621 Assessment of Appetite-Regulating Hormones Provides Further Evidence of Altered
- Adipoinsular Axis in Early Psychosis. Front. Psychiatry 11, 480. 622
- 623 https://doi.org/10.3389/fpsyt.2020.00480
- Makowski, D., Ben-Shachar, M.S., Chen, S.H.A., Lüdecke, D., 2019a. Indices of Effect Existence and 624 Significance in the Bayesian Framework. Front. Psychol. 10. 625
- https://doi.org/10.3389/fpsyg.2019.02767 626
- 627 Makowski, D., Ben-Shachar, M.S., Lüdecke, D., 2019b. bayestestR: Describing Effects and their
- Uncertainty, Existence and Significance within the Bayesian Framework. J. Open Source 628
- Softw. 4, 1541. https://doi.org/10.21105/joss.01541 629
- McElreath, R., 2018. Statistical Rethinking: A Bayesian Course with Examples in R and Stan, 630
- 631 Statistical Rethinking: A Bayesian Course with Examples in R and Stan.
- 632 https://doi.org/10.1201/9781315372495

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

Metcalf, S.A., Jones, P.B., Nordstrom, T., Timonen, M., Mäki, P., Miettunen, J., Jääskeläinen, E., 633

- Järvelin, M.-R., Stochl, J., Murray, G.K., Veijola, J., Khandaker, G.M., 2017. Serum C-reactive 634
- 635 protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study.
- 636 Brain. Behav. Immun. 59, 253–259. https://doi.org/10.1016/j.bbi.2016.09.008
- Milaneschi, Y., Kappelmann, N., Ye, Z., Lamers, F., Moser, S., Jones, P.B., Burgess, S., Penninx, 637
- 638 B.W.J.H., Khandaker, G.M., 2021. Association of inflammation with depression and anxiety:
- evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts. 639
- 640 Mol. Psychiatry. https://doi.org/10.1038/s41380-021-01188-w
- Milaneschi, Y., Lamers, F., Berk, M., Penninx, B.W.J.H., 2020. Depression Heterogeneity and Its 641
- Biological Underpinnings: Toward Immunometabolic Depression. Biol. Psychiatry, Molecular 642
- Underpinnings of Depression and Its Treatment 88, 369–380. 643
- https://doi.org/10.1016/j.biopsych.2020.01.014 644
- Milaneschi, Y., Lamers, F., Peyrot, W.J., Baune, B.T., Breen, G., Dehghan, A., Forstner, A.J., Grabe, 645
- H.J., Homuth, G., Kan, C., Lewis, C., Mullins, N., Nauck, M., Pistis, G., Preisig, M., Rivera, M., 646
- Rietschel, M., Streit, F., Strohmaier, J., Teumer, A., Van der Auwera, S., Wray, N.R., 647
- 648 Boomsma, D.I., Penninx, B.W.J.H., for the CHARGE Inflammation Working Group and the
- 649 Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, 2017.
- 650 Genetic Association of Major Depression With Atypical Features and Obesity-Related
- Immunometabolic Dysregulations. JAMA Psychiatry 74, 1214–1225. 651
- 652 https://doi.org/10.1001/jamapsychiatry.2017.3016
- Milaneschi, Y., Simmons, W.K., van Rossum, E.F.C., Penninx, B.W., 2019. Depression and obesity: 653 654 evidence of shared biological mechanisms. Mol. Psychiatry 24, 18–33.
- 655 https://doi.org/10.1038/s41380-018-0017-5
- 656 Northstone, K., Lewcock, M., Groom, A., Boyd, A., Macleod, J., Timpson, N., Wells, N., 2019. The
- Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled sample 657
- 658 of index children in 2019. Wellcome Open Res. 4, 51.
- 659 https://doi.org/10.12688/wellcomeopenres.15132.1
- Ong, K.K., Petry, C.J., Emmett, P.M., Sandhu, M.S., Kiess, W., Hales, C.N., Ness, A.R., Dunger, D.B., 660
- 661 ALSPAC study team, 2004. Insulin sensitivity and secretion in normal children related to size at

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 662 birth, postnatal growth, and plasma insulin-like growth factor-I levels. Diabetologia 47, 1064-
- 1070. https://doi.org/10.1007/s00125-004-1405-8 663
- 664 Osimo, E.F., Baxter, L.J., Lewis, G., Jones, P.B., Khandaker, G.M., 2019. Prevalence of low-grade 665 inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol.
- Med. 49, 1958–1970. https://doi.org/10.1017/S0033291719001454 666
- Penninx, B.W., Beekman, A.T., Honig, A., Deeg, D.J., Schoevers, R.A., van Eijk, J.T., van Tilburg, W., 667
- 668 2001. Depression and cardiac mortality: results from a community-based longitudinal study.
- Arch. Gen. Psychiatry 58, 221-227. https://doi.org/10.1001/archpsyc.58.3.221 669
- 670 Perry, B.I., Burgess, S., Jones, H.J., Zammit, S., Upthegrove, R., Mason, A.M., Day, F.R.,
- Langenberg, C., Wareham, N.J., Jones, P.B., Khandaker, G.M., 2021a. The potential shared 671
- role of inflammation in insulin resistance and schizophrenia: A bidirectional two-sample 672
- mendelian randomization study. PLoS Med. 18, e1003455. 673
- https://doi.org/10.1371/journal.pmed.1003455 674
- Perry, B.I., McIntosh, G., Weich, S., Singh, S., Rees, K., 2016. The association between first-episode 675 676 psychosis and abnormal glycaemic control: systematic review and meta-analysis. Lancet 677 Psychiatry 3, 1049–1058. https://doi.org/10.1016/S2215-0366(16)30262-0
- Perry, B.I., Stochl, J., Upthegrove, R., Zammit, S., Wareham, N., Langenberg, C., Winpenny, E., 678
- Dunger, D., Jones, P.B., Khandaker, G.M., 2021b. Longitudinal Trends in Childhood Insulin 679
- 680 Levels and Body Mass Index and Associations With Risks of Psychosis and Depression in Young Adults. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2020.4180
- Perry, B.I., Upthegrove, R., Thompson, A., Marwaha, S., Zammit, S., Singh, S.P., Khandaker, G., 682
- 2019. Dvsglvcaemia. Inflammation and Psychosis: Findings From the UK ALSPAC Birth 683
- Cohort. Schizophr. Bull. 45, 330–338. https://doi.org/10.1093/schbul/sby040 684
- 685 Pillinger, T., Beck, K., Gobjila, C., Donocik, J.G., Jauhar, S., Howes, O.D., 2017. Impaired Glucose
- Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis. JAMA 686 Psychiatry 74, 261–269. https://doi.org/10.1001/jamapsychiatry.2016.3803 687
- Pulito-Cueto, V., Remuzgo-Martínez, S., Genre, F., Calvo-Alén, J., Aurrecoechea, E., Llorente, I., 688
- Triguero-Martinez, A., Blanco, R., Llorca, J., Ruiz-Lucea, E., Rivera-García, N., Gualillo, O., 689

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- López-Mejías, R., Castañeda, S., González-Gay, M.A., 2020. Anti-IL-6 therapy reduces leptin 690
- serum levels in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 691
- 692 R Development Core Team, 2017. R: A Language and environment for statistical computing. Vienna 693 Austria R Found. Stat. Comput.
- Stefanis, N.C., Hanssen, M., Smirnis, N.K., Avramopoulos, D.A., Evdokimidis, I.K., Stefanis, C.N., 694
- 695 Verdoux, H., Van Os, J., 2002. Evidence that three dimensions of psychosis have a distribution
- 696 in the general population. Psychol. Med. 32, 347-358.
- https://doi.org/10.1017/s0033291701005141 697
- Strauss, G.P., Whearty, K.M., Morra, L.F., Sullivan, S.K., Ossenfort, K.L., Frost, K.H., 2016. Avolition 698
- 699 in schizophrenia is associated with reduced willingness to expend effort for reward on a
- 700 Progressive Ratio task. Schizophr. Res. 170, 198-204.
- 701 https://doi.org/10.1016/j.schres.2015.12.006
- 702 Stubbs, B., Wang, A.K., Vancampfort, D., Miller, B.J., 2016. Are leptin levels increased among people 703 with schizophrenia versus controls? A systematic review and comparative meta-analysis.
- 704 Psychoneuroendocrinology 63, 144–154. https://doi.org/10.1016/j.psyneuen.2015.09.026
- 705 Sullivan, S.A., Kounali, D., Cannon, M., David, A.S., Fletcher, P.C., Holmans, P., Jones, H., Jones,
- 706 P.B., Linden, D.E.J., Lewis, G., Owen, M.J., O'Donovan, M., Rammos, A., Thompson, A.,
- Wolke, D., Heron, J., Zammit, S., 2020. A Population-Based Cohort Study Examining the 707
- 708 Incidence and Impact of Psychotic Experiences From Childhood to Adulthood, and Prediction
- 709 of Psychotic Disorder. Am. J. Psychiatry 177, 308-317.
- 710 https://doi.org/10.1176/appi.ajp.2019.19060654
- Sun, F., Lei, Y., You, J., Li, C., Sun, L., Garza, J., Zhang, D., Guo, M., Scherer, P.E., Lodge, D., Lu, 711
- X.-Y., 2019. Adiponectin modulates ventral tegmental area dopamine neuron activity and 712
- 713 anxiety-related behavior through AdipoR1. Mol. Psychiatry 24, 126–144.
- https://doi.org/10.1038/s41380-018-0102-9 714
- Timpson, N.J., Nordestgaard, B.G., Harbord, R.M., Zacho, J., Frayling, T.M., Tybjærg-Hansen, A., 715
- Davey Smith, G., 2011. C-reactive protein levels and body mass index: elucidating direction of 716
- causation through reciprocal Mendelian randomization. Int. J. Obes. 35, 300-308. 717
- https://doi.org/10.1038/ijo.2010.137 718

It is made available under a CC-BY-ND 4.0 International license Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

van Dielen, F.M.H., van't Veer, C., Schols, A.M., Soeters, P.B., Buurman, W.A., Greve, J.W.M., 2001.

- 720 Increased leptin concentrations correlate with increased concentrations of inflammatory
- 721 markers in morbidly obese individuals. Int. J. Obes. 25, 1759–1766.
- 722 https://doi.org/10.1038/sj.ijo.0801825
- van Melle, J.P., de Jonge, P., Spijkerman, T.A., Tijssen, J.G.P., Ormel, J., van Veldhuisen, D.J., van
- den Brink, R.H.S., van den Berg, M.P., 2004. Prognostic association of depression following
- myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom.
- 726 Med. 66, 814–822. https://doi.org/10.1097/01.psy.0000146294.82810.9c
- Vancampfort, D., Stubbs, B., Mitchell, A.J., Hert, M.D., Wampers, M., Ward, P.B., Rosenbaum, S.,
- 728 Correll, C.U., 2015. Risk of metabolic syndrome and its components in people with
- schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder:
- a systematic review and meta-analysis. World Psychiatry 14, 339–347.
- 731 https://doi.org/10.1002/wps.20252
- Vanes, L.D., Mouchlianitis, E., Collier, T., Averbeck, B.B., Shergill, S.S., 2018. Differential neural
  reward mechanisms in treatment-responsive and treatment-resistant schizophrenia. Psychol.
  Med. 48, 2418–2427. https://doi.org/10.1017/S0033291718000041
- 735 Wagenmakers, E.-J., Marsman, M., Jamil, T., Ly, A., Verhagen, J., Love, J., Selker, R., Gronau, Q.F.,
- <sup>736</sup> Šmíra, M., Epskamp, S., Matzke, D., Rouder, J.N., Morey, R.D., 2018. Bayesian inference for
- psychology. Part I: Theoretical advantages and practical ramifications. Psychon. Bull. Rev. 25,
  35–57. https://doi.org/10.3758/s13423-017-1343-3
- Wang, J., Huang, J., Yang, X.-H., Lui, S.S.Y., Cheung, E.F.C., Chan, R.C.K., 2015. Anhedonia in
  schizophrenia: Deficits in both motivation and hedonic capacity. Schizophr. Res. 168, 465–474.
  https://doi.org/10.1016/j.schres.2015.06.019
- Wolf, D.H., Satterthwaite, T.D., Kantrowitz, J.J., Katchmar, N., Vandekar, L., Elliott, M.A., Ruparel, K.,
   2014. Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and
- imaging measures. Schizophr. Bull. 40, 1328–1337. https://doi.org/10.1093/schbul/sbu026
- 745 Yudkin, J.S., Stehouwer, C.D.A., Emeis, J.J., Coppack, S.W., 1999. C-Reactive Protein in Healthy
- 746 Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction.
- 747 Arterioscler. Thromb. Vasc. Biol. 19, 972–978. https://doi.org/10.1161/01.ATV.19.4.972

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- Zalli, A., Jovanova, O., Hoogendijk, W.J.G., Tiemeier, H., Carvalho, L.A., 2016. Low-grade 748
- inflammation predicts persistence of depressive symptoms. Psychopharmacology (Berl.) 233, 749
- 750 1669-1678. https://doi.org/10.1007/s00213-015-3919-9
- 751 Zammit, S., Kounali, D., Cannon, M., David, A.S., Gunnell, D., Heron, J., Jones, P.B., Lewis, S.,
- 752 Sullivan, S., Wolke, D., Lewis, G., 2013. Psychotic experiences and psychotic disorders at age
- 753 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort
- 754 study. Am. J. Psychiatry 170, 742-750. https://doi.org/10.1176/appi.ajp.2013.12060768